Copyright
©The Author(s) 2015.
World J Gastroenterol. Jan 28, 2015; 21(4): 1182-1188
Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1182
Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1182
Table 2 Comparison of postoperative recurrence risk subgroups: 4-wk follow up to gastrointestinal vs colorectal surgery and 12 mo care measures n (%)
Postoperative follow-up at 4 wk | Postoperative 12 mo | ||||
With GI | With colorectal surgery | P-value | Colonoscopy | Medical therapy resumption | |
Overall (n = 88) | 36 (40.9) | 81 (92.0) | < 0.0001 | 47 (53.4) | 66 (75.0) |
Patient subgroups: | |||||
Less than 10 yr since diagnosis or B2 disease (n = 35) | 13 (37.1) | 33 (94.3) | < 0.0001 | 20 (57.1) | 18 (51.4) |
2 or more surgeries (n = 38) | 16 (42.1) | 36 (94.7) | < 0.0001 | 21 (84.0) | 25 (65.8) |
B3 disease (n = 30) | 16 (53.3) | 28 (93.3) | 0.0009 | 15 (50.0) | 16 (53.3) |
Current smokers (n = 23) | 8 (34.8) | 21 (91.3) | 0.0001 | 14 (60.9) | 17 (73.9) |
Preoperative anti-TNF (n = 38) | 20 (52.6) | 35 (92.1) | 0.0002 | 20 (52.6) | 25 (65.8) |
Preoperative Immunomodulator (n = 19) | 9 (47.4) | 19 (100.0) | 0.0004 | 10 (52.6) | 12 (63.2) |
Preoperative steroids (n = 35) | 17 (48.6) | 33 (94.3) | < 0.0001 | 20 (57.1) | 26 (74.3) |
- Citation: Bennett JL, Ha CY, Efron JE, Gearhart SL, Lazarev MG, Wick EC. Optimizing perioperative Crohn's disease management: Role of coordinated medical and surgical care. World J Gastroenterol 2015; 21(4): 1182-1188
- URL: https://www.wjgnet.com/1007-9327/full/v21/i4/1182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i4.1182